Health&Beauty- Page 34

The FINANCIAL -- THOUSAND OAKS, Calif.,-- Amgen and AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma without an eosinophilic phenotype.

The FINANCIAL -- An estimated 32,500 children in 11 states from California to New York will benefit from the Healthy Eyes Healthy Children Community Grants (HEHC) program. HEHC, in its second year, is funded by Essilor Vision Foundation, which also supports the program with

The FINANCIAL -- University of Liverpool scientists have been boosted £1m by the Medical Research Council to research the brain mechanisms contributing to cognitive problems and treatment outcome in people with a new diagnosis of epilepsy.

The FINANCIAL -- The number of adults aged 85 plus needing round-the-clock care in England will almost double to 446,000 over the next 20 years, according to new research from the LSE-led MODEM study, published in the Lancet Public Health.

The FINANCIAL -- Shanghai, China, September 3rd, 2018 – BeiGene Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, announced that the National Medical Products Administration of China (NMPA, formerly known

The FINANCIAL -- Amid raging wildfires in California, and as it is entered what the National Oceanic and Atmospheric Administration calls the most active and dangerous time of year for tropical cyclone activity, heed these emergency procedure tips from doctors who have

The FINANCIAL -- PRINCETON, N.J.-- Bristol-Myers Squibb Company announced that Christopher Boerner, Ph.D., has been appointed executive vice president and chief commercial officer, effective immediately. Boerner succeeds Murdo Gordon, who departed the company on August 3, 2018, to pursue another opportunity.

The FINANCIAL -- Glaucomatous neurodegeneration may stem from a case of mistaken identities after high intraocular pressure (IOP) triggers an autoimmune response that targets retinal cells, new evidence suggests.

The FINANCIAL -- Basel, August 29, 2018 - Novartis announced that the European Commission (EC) has approved Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for the adjuvant treatment of stage III patients with BRAF V600 mutation-positive melanoma after complete surgical resection.